Oncogene

Fore Biotherapeutics Issues Statement

Retrieved on: 
Thursday, December 2, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Oncogene, Intellectual property, Food and Drug Administration, Cancer, Hope, BRAF, Foresight, Twitter, Genomics, LinkedIn, Machine learning, CEO, Food, Company

Fore Biotherapeutics , a precision oncology company focused on providing people with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines using its proprietary functional genomics platform, today issued the following statement:

Key Points: 
  • Fore Biotherapeutics , a precision oncology company focused on providing people with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines using its proprietary functional genomics platform, today issued the following statement:
    Effective immediately, Usama Malik is no longer a Director or Chief Executive Officer of Fore Biotherapeutics.
  • The charges in no way relate to privately-held Fore Biotherapeutics, its employees or operations, and Fore Biotherapeutics expects no impact to such operations.
  • As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines.
  • Fore Biotherapeutics undertakes no obligation to update any forward-looking statement, except as required by law.

HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical

Retrieved on: 
Thursday, December 2, 2021
Molecule, Patient, Lung, SHP2, CEO, Safety, Cerebro, Nephrology, Company, Oncogene, Clinical trial, SAN, GTP, Therapy, R, HERG, Metastasis, Pediatrics, NMPA, KRAS, Pharmaceutical industry

SAN DIEGO, Dec. 2, 2021 /PRNewswire/ -- HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, from Shanghai Jemincare Pharmaceutical Co., Ltd. Jemincare will retain the relevant rights in the greater China area.

Key Points: 
  • SAN DIEGO, Dec. 2, 2021 /PRNewswire/ -- HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, from Shanghai Jemincare Pharmaceutical Co., Ltd. Jemincare will retain the relevant rights in the greater China area.
  • Mr. Hong Liang, President of Jemincare Pharmaceutical Group, said, "Weare delighted to work with HUYABIO to explore global development of this unique KRAS inhibitor.
  • HUYABIO has generated a lot of experience to bring innovative drugs from China to global market.
  • JMKX1899 is a KRAS inhibitor independently developed by Jemincare.

Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO

Retrieved on: 
Tuesday, November 30, 2021
Molecule, Patient, Lung, CEO, Safety, Cerebro, Nephrology, Company, Oncogene, GTP, Therapy, R, HERG, PR, Metastasis, US FDA, SHP, Pediatrics, NMPA, KRAS, Pharmaceutical industry

SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- Jemincare, a leading pharmaceutical company from China, announced today its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., had licensed exclusive worldwide ex-China rights to the Kras inhibitor, JMKX1899,to HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations.

Key Points: 
  • SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- Jemincare, a leading pharmaceutical company from China, announced today its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., had licensed exclusive worldwide ex-China rights to the Kras inhibitor, JMKX1899,to HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations.
  • Targeting the GTP pocket of Kras in the switch-II region, which has made Kras druggable, enables the development of more potent and potentially effective inhibitors.
  • JMKX1899 is a KRAS inhibitor independently developed by Jemincare.
  • Mr. Hong Liang, President of Jemincare Pharmaceutical Group, said, "Weare delighted to work with HUYABIO to explore global development of this unique KRAS inhibitor.

Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO

Retrieved on: 
Tuesday, November 30, 2021
Molecule, Patient, Lung, CEO, Safety, Cerebro, Nephrology, Company, Oncogene, GTP, Therapy, R, View, HERG, PR, Metastasis, US FDA, SHP, Pediatrics, Multimedia, NMPA, KRAS, Pharmaceutical industry

SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- Jemincare, a leading pharmaceutical company from China, announced today its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., had licensed exclusive worldwide ex-China rights to the Kras inhibitor, JMKX1899,to HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations.

Key Points: 
  • SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- Jemincare, a leading pharmaceutical company from China, announced today its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., had licensed exclusive worldwide ex-China rights to the Kras inhibitor, JMKX1899,to HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations.
  • Targeting the GTP pocket of Kras in the switch-II region, which has made Kras druggable, enables the development of more potent and potentially effective inhibitors.
  • JMKX1899 is a KRAS inhibitor independently developed by Jemincare.
  • Mr. Hong Liang, President of Jemincare Pharmaceutical Group, said, "Weare delighted to work with HUYABIO to explore global development of this unique KRAS inhibitor.

Frontier Medicines Announces the Appointment of Marguerite Hutchinson, J.D., as Chief Business Officer

Retrieved on: 
Wednesday, November 17, 2021
Patient, Harvard University, CEO, Industry, TGCT, Oncogene, University of San Diego School of Law, Cancer, Precision medicine, SAN, University, Program, UCSF, Intellectual property, Woman, Machine learning, Twitter, Mutation, GLOBE, Patent, UCSF Helen Diller Family Comprehensive Cancer Center, AbbVie, Frontier, Proteome, LinkedIn, Disease, Tenosynovial giant cell tumor, KRAS, Pharmaceutical industry

We are pleased to welcome Marguerite to our executive leadership team at Frontier, said Chris Varma, Ph.D., chairman, CEO, and co-founder of Frontier Medicines.

Key Points: 
  • We are pleased to welcome Marguerite to our executive leadership team at Frontier, said Chris Varma, Ph.D., chairman, CEO, and co-founder of Frontier Medicines.
  • Ms. Hutchinson was most recently the chief operating officer and general counsel of Plexxikon, overseeing all finance and operational aspects of the company, including business development, legal affairs, intellectual property and project management.
  • Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable.
  • For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter .

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 10, 2021
Lymphatic system, VAV1, Biodata, Private Securities Litigation Reform Act, Therapy, R, NASDAQ, CEO, Oncogene, Food, N-Myc, Rational design, BCL11A, Cell death, Russell, COVID-19, Administration, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Squamous cell carcinoma, Program, Finance, Proteomics, Cancer, AACR, Public expenditure, File, Multiple myeloma, Protein, MGD, Research and development, Company, GLOBE, Conference, CDK2, Large-cell lung carcinoma, Myc, U.S. Securities and Exchange Commission, GSPT1, Precision medicine, Apoptosis, Cell, FDA, IND, Fine chemical, Pharmaceutical industry, Video game

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue-based precision medicines, today reported business highlights and financial results for the third quarter, ended Sept. 30, 2021.

Key Points: 
  • Owen Wallace, Ph.D., Chief Scientific Officer of Monte Rosa, added, Advancing our first development candidate into IND-enabling activities is one of the most important milestones for our company to date.
  • Selected first development candidate, MRT-2359, targeting GSPT1 and initiated IND-enabling activities.
  • Net Loss: Net loss for the third quarter of 2021 was $19.8 million, compared to $6.6 million for the third quarter of 2020.
  • Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader precision medicines.

Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 8, 2021
Diamond, PK, FGFR, Lung cancer, Cancer, Private Securities Litigation Reform Act, Perk, Class, Clinical trial, R, Oncogene, Human, GBM, Vemurafenib, Investment, M26 Modular Accessory Shotgun System, Hyperphosphatemia, COVID-19, NEW, EGFR, Program, Annual report, Partnership, FGFR2, Conference, Company, Research, Black Diamond, Glioblastoma, Large-cell lung carcinoma, GLOBE, U.S. Securities and Exchange Commission, NSCLC, Drug discovery, BRAF, FGFR1, MAP, OpenEye Scientific Software, FGFR3, Nasdaq, Cell, Encorafenib, Patient, Dyckman Street station (IND Eighth Avenue Line), Pharmaceutical industry, Antibiotics, Trapping, Medical imaging, Lithium

and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • Black Diamond remains on-track with preparations for initiating the Phase 2 portion of the MasterKey-01 Phase 1/2 study of BDTX-189 by the end of 2021.
  • Black Diamond continues to advance BDTX-1535 through IND-enabling studies and expects to file an IND application by the first half of 2022.
  • Black Diamond continues to progress its early-stage pipeline programs designed to target cancers driven by mutations in BRAF and FGFR.

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

Retrieved on: 
Monday, October 18, 2021
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, American Cancer Society, Risk, Methylation, Cell, Incidence, ADR, Blood, Cancer, Hematological Cancer Research Investment and Education Act, Senior, Heart, AML, Growth, Accent, RNA transfection, Protein, Therapy, RMP, METTL14, McNeil Consumer Healthcare, METTL3, RNA, Development, Neglected tropical disease research and development, Clinical trial, Patient, Biology, Data, Acute myeloid leukemia, Oncogene, Bone marrow, Apoptosis, SLAS Discovery, Patent, Aichi M6A, IPN, Pharmaceutical industry

Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.

Key Points: 
  • Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.
  • Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development, Ipsen, said Oncology is a key focus area for Ipsen as we grow our pipeline.
  • We are delighted to partner with Accent to progress the METTL3 program as we continue our expansion into hematologic oncology.
  • Accent Therapeutics novel investigational small molecule inhibitors of METTL3 seek to treat specific sub-types of AML with high unmet medical need.

bioAffinity Technologies Announces Xavier T. Reveles Promoted to Vice President of Operations

Retrieved on: 
Thursday, October 14, 2021
Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Lung, Patient, HIV disease progression rates, Technology, Diabetes, Diagnosis, COVID-19, Cancer, Publication, Pathology, UT Health San Antonio Cancer Center, LDT, Physician, Prostate, Flow cytometry, Laboratory, Breast, Therapy, American Society for Clinical Pathology, Multimedia, Disease, Cytogenetics, Invitae, Schizophrenia, CLIA, Roger Revelle, Society, CG, University, Research, Company, Oncogene, 2021 Essex County Council election, University of Texas Health Science Center at San Antonio, Lung cancer, CAP, Acquisition, Medical imaging

bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations.

Key Points: 
  • bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations.
  • Reveles will be responsible for overseeing the commercialization of the Companys diagnostic products, including CyPath Lung, a highly accurate, non-invasive test to diagnose early-stage lung cancer.
  • Prior to joining bioAffinity, Mr. Reveles was Laboratory Director for Oncopath Laboratory START Cancer Center in San Antonio, Texas.
  • bioAffinity Technologies, Inc. ( www.bioaffinitytech.com ) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 8, 2021
Diamond, Private Securities Litigation Reform Act, Company, Brain, Neoplasm, Large-cell lung carcinoma, MAP, EGFR, Conference, Drug discovery, BRAF, M26 Modular Accessory Shotgun System, COVID-19, NEW, Black Diamond, Cell, Program, GBM, GLOBE, FGFR2, Investigational New Drug, Cancer, Precision medicine, Annual report, Glioblastoma, Class, Mutation, FGFR1, U.S. Securities and Exchange Commission, Hyperphosphatemia, Vemurafenib, Human, Toxic shock syndrome toxin, Dyckman Street station (IND Eighth Avenue Line), AACR, FGFR3, FGFR, Perk, Encorafenib, Oncogene, Patient, Secondary malignant neoplasm, Nasdaq, Pharmaceutical industry, Medical imaging, Antibiotics, Vaccine, Trapping, Abrasive

Black Diamond expects to file an Investigational New Drug (IND) application for BDTX-1535 in the first half of 2022.

Key Points: 
  • Black Diamond expects to file an Investigational New Drug (IND) application for BDTX-1535 in the first half of 2022.
  • The presentations from the AACR-NCI-EORTC meeting are available on the Scientific Presentations and Publications section of the Black Diamond Therapeutics website.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
  • Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com .